High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France - Sorbonne Université Access content directly
Journal Articles Revue Neurologique Year : 2022

High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France

Nicolas Villain
  • Function : Author
  • PersonId : 1133683
R Levy
  • Function : Author
  • PersonId : 1235202
  • IdHAL : rachel-levy
Fichier principal
Vignette du fichier
Villain2022_Part2.pdf (777.57 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

hal-03852664 , version 1 (15-11-2022)

Identifiers

Cite

Nicolas Villain, V Planche, R Levy. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France. Revue Neurologique, In press, ⟨10.1016/j.neurol.2022.08.002⟩. ⟨hal-03852664⟩
29 View
66 Download

Altmetric

Share

Gmail Facebook X LinkedIn More